the next slide is just a quick visual showing the transition from the old generation to the new generation of atypicals. Despite all what the CATIE data have shown in terms of similarity and discontinuation rates, there are numerous reasons why the atypicals have actually replaced the conventionals. Every practitioner who treats schizophrenia, like myself, remembers what our patients looked like, how much they suffered from side effects and poor outcomes in the old days, and we certainly do not feel that going backward is justifiable at this time, even though some patients may benefit from small doses of the conventionals. In my opinion, most of the patients still benefit greatly from the atypicals if we choose wisely and match the patient with the drug.